MCID: VST006
MIFTS: 28

Vestibulocochlear Nerve Disease malady

Categories: Ear diseases, Neuronal diseases

Aliases & Classifications for Vestibulocochlear Nerve Disease

Aliases & Descriptions for Vestibulocochlear Nerve Disease:

Name: Vestibulocochlear Nerve Disease 12 14
Vestibulocochlear Nerve Diseases 42 69
Cochlear Nerve Diseases 69
Acoustic Nerve Disease 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12657
ICD10 33 H93.3 H93.3X
ICD9CM 35 388.5
MeSH 42 D000160
NCIt 47 C27207
SNOMED-CT 64 194402005 77949003
UMLS 69 C0001163

Summaries for Vestibulocochlear Nerve Disease

MalaCards based summary : Vestibulocochlear Nerve Disease, also known as vestibulocochlear nerve diseases, is related to laryngitis and hermansky-pudlak syndrome 3, and has symptoms including earache An important gene associated with Vestibulocochlear Nerve Disease is RTEL1 (Regulator Of Telomere Elongation Helicase 1), and among its related pathways/superpathways is Calcium signaling pathway. The drugs Methylprednisolone and Prednisolone have been mentioned in the context of this disorder. Affiliated tissues include brain, and related phenotype is Increased shRNA abundance (Z-score > 2).

Wikipedia : 71 The vestibulocochlear nerve (auditory vestibular nerve), known as the eighth cranial nerve, transmits... more...

Related Diseases for Vestibulocochlear Nerve Disease

Diseases related to Vestibulocochlear Nerve Disease via text searches within MalaCards or GeneCards Suite gene sharing:

id Related Disease Score Top Affiliating Genes
1 laryngitis 10.0 CACNA1A RTEL1
2 hermansky-pudlak syndrome 3 9.9 ATP2B3 CACNA1A
3 acute interstitial pneumonia 9.7 ATP2B3 CACNA1A
4 blastomycosis 9.1 ARHGEF1 ATP2B3 CACNA1A PIR RTEL1 SALL1
5 locked-in syndrome 9.1 ARHGEF1 ATP2B3 CACNA1A PIR RTEL1 SALL1

Graphical network of the top 20 diseases related to Vestibulocochlear Nerve Disease:



Diseases related to Vestibulocochlear Nerve Disease

Symptoms & Phenotypes for Vestibulocochlear Nerve Disease

UMLS symptoms related to Vestibulocochlear Nerve Disease:


earache

GenomeRNAi Phenotypes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-101 9.73 SALL1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.73 SALL1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-13 9.73 SALL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.73 ARHGEF1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.73 SALL1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.73 ARHGEF1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.73 ARHGEF1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.73 SALL1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.73 SALL1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.73 ARHGEF1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.73 ARHGEF1 SALL1
12 Synthetic lethal with vaccinia virus (VACV) infection GR00362-A 8.8 CACNA1A PIR SALL1

Drugs & Therapeutics for Vestibulocochlear Nerve Disease

Drugs for Vestibulocochlear Nerve Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 101)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3 83-43-2 6741
2
Prednisolone Approved, Vet_approved Phase 4,Phase 3 50-24-8 5755
3
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
4 Antiemetics Phase 4,Phase 3
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
6 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
7 Autonomic Agents Phase 4,Phase 3
8 Gastrointestinal Agents Phase 4,Phase 3
9 glucocorticoids Phase 4,Phase 3,Phase 2
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Methylprednisolone acetate Phase 4,Phase 3
14 Methylprednisolone Hemisuccinate Phase 4,Phase 3
15 Neuroprotective Agents Phase 4,Phase 3
16 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
17 Prednisolone acetate Phase 4,Phase 3
18 Prednisolone hemisuccinate Phase 4,Phase 3
19 Prednisolone phosphate Phase 4,Phase 3
20 Protective Agents Phase 4,Phase 3
21 Anti-Bacterial Agents Phase 4,Phase 2,Early Phase 1
22 Anti-Infective Agents Phase 4,Phase 2,Early Phase 1
23 Gentamicins Phase 4
24 Anti-Asthmatic Agents Phase 4,Phase 3
25 Betamethasone benzoate Phase 4
26 Betamethasone sodium phosphate Phase 4
27 Betamethasone Valerate Phase 4 2152-44-5
28 Betamethasone-17,21-dipropionate Phase 4
29 Respiratory System Agents Phase 4,Phase 3
30 Ophthalmic Solutions Phase 4
31 Tetrahydrozoline Phase 4
32
Ethanol Approved Phase 3 64-17-5 702
33
Glycerol Approved, Experimental Phase 3 56-81-5 753
34
Cilostazol Approved Phase 3 73963-72-1 2754
35 Complement System Proteins Phase 3
36 Micronutrients Phase 3
37 Trace Elements Phase 3
38 Ubiquinone Phase 3
39 Vitamins Phase 3
40 Fibrinolytic Agents Phase 3,Phase 2
41 Platelet Aggregation Inhibitors Phase 3,Phase 2
42 Bronchodilator Agents Phase 3
43 Phosphodiesterase 3 Inhibitors Phase 3
44 Phosphodiesterase Inhibitors Phase 3
45 Vasodilator Agents Phase 3
46 Ginkgo Nutraceutical Phase 3
47
Coenzyme Q10 Experimental, Nutraceutical Phase 3 303-98-0 5281915
48 Lecithin Nutraceutical Phase 3
49
Everolimus Approved Phase 2,Early Phase 1 159351-69-6 6442177
50
Miconazole Approved, Investigational, Vet_approved Phase 2,Early Phase 1 22916-47-8 4189

Interventional clinical trials:

(show top 50) (show all 72)
id Name Status NCT ID Phase
1 Acute Unilateral Vestibulopathy and Corticosteroid Treatment Recruiting NCT02912182 Phase 4
2 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4
3 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4
4 Cacicol20® in Corneal Wound Healing and Nerve Regeneration After Phototherapeutic Keratectomy Terminated NCT02373397 Phase 4
5 The Efficacy of Steroid Therapy in Vestibular Neuritis Unknown status NCT02098330 Phase 3
6 Stereotactic Radiation in Vestibular Schwannoma Unknown status NCT01449604 Phase 3
7 Evolution of Albumin on AOA1 Patients Supplemented With Coenzyme Q10 Recruiting NCT02333305 Phase 3
8 Vestibular Schwannoma - Radiosurgery or Expectation: V-REX. Recruiting NCT02249572 Phase 2, Phase 3
9 Cyberknife Radiosurgery for Patients With Neurinomas Recruiting NCT02055859 Phase 3
10 Effect of Renexin Tablet in Patients With Recurrent Vestibulopathy Terminated NCT01895400 Phase 3
11 Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients Completed NCT01490476 Phase 2
12 Complementary/Alternative Medicine for Abnormality in the Vestibular (Balance) System Completed NCT00032383 Phase 1, Phase 2
13 Bevacizumab for Symptomatic Vestibular Schwannoma in Neurofibromatosis Type 2 (NF2) Completed NCT01207687 Phase 2
14 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2
15 Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2 Completed NCT01419639 Phase 2
16 Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT02104323 Phase 2
17 Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Completed NCT00973739 Phase 2
18 Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2 Completed NCT00004437 Phase 2
19 Study of Axitinib in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Recruiting NCT02129647 Phase 2
20 Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors Recruiting NCT02934256 Phase 2
21 AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas Recruiting NCT02831257 Phase 2
22 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2
23 Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma Recruiting NCT01345136 Phase 2
24 Hearing Outcomes Using Fractionated Proton Radiation Therapy for Vestibular Schwannoma Recruiting NCT01199978 Phase 2
25 Phase 2 Study of Bevacizumab in Children and Young Adults With NF 2 and Progressive Vestibular Schwannomas Active, not recruiting NCT01767792 Phase 2
26 Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas Active, not recruiting NCT01125046 Phase 2
27 Study of Aspirin in Patients With Vestibular Schwannoma Not yet recruiting NCT03079999 Phase 2
28 PTC299 for Treatment of Neurofibromatosis Type 2 Suspended NCT00911248 Phase 2
29 A Study of Nilotinib in Growing Vestibular Schwannomas Terminated NCT01201538 Phase 2
30 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1
31 An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors Completed NCT00030043 Phase 1
32 Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma Suspended NCT01083966 Phase 1
33 Characterisation of Cortical Vestibular Evoked Potentials (C-VEPs) Unknown status NCT02463695
34 Concentration and Activity of Lapatinib in Vestibular Schwannomas Unknown status NCT00863122 Early Phase 1
35 Transplantation of Tissue Cultured Human Amniotic Epithelial Cells Onto Damaged Ocular Surfaces Unknown status NCT00344708
36 Vestibular System in Migrainous Vertigo Patients Unknown status NCT00901953
37 Vestibular Schwannoma and Psychological Factors Unknown status NCT01743248
38 The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis Unknown status NCT01231009 Early Phase 1
39 Effect of Implant Position on Magnetic Resonance Image Distortion Unknown status NCT02246231
40 NF2 Natural History Consortium Unknown status NCT00004483
41 Longitudinal Study Of The Evoked Compound Action Potential Measured In Children Cochlear Implant Users Completed NCT00725998
42 Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients Completed NCT01222728
43 Home-based Computer Gaming in Vestibular Rehabilitation Completed NCT01943955
44 Optimizing the Ocular Surface Prior to Cataract Surgery Completed NCT02766907
45 Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype Completed NCT02298270
46 Recovery of Visual Acuity in People With Vestibular Deficits Completed NCT00411216
47 Clinical Evaluation of a Novel Balance, Vestibular and Oculomotor Assessment Tool Completed NCT02171312
48 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896
49 Safety and Effectiveness of the MED-EL Electric-Acoustic System Completed NCT00747435
50 Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia Completed NCT00149734

Search NIH Clinical Center for Vestibulocochlear Nerve Disease

Cochrane evidence based reviews: vestibulocochlear nerve diseases

Genetic Tests for Vestibulocochlear Nerve Disease

Anatomical Context for Vestibulocochlear Nerve Disease

MalaCards organs/tissues related to Vestibulocochlear Nerve Disease:

39
Brain

Publications for Vestibulocochlear Nerve Disease

Articles related to Vestibulocochlear Nerve Disease:

id Title Authors Year
1
Facial and vestibulocochlear nerve disease in six horses. ( 6643213 )
1983

Variations for Vestibulocochlear Nerve Disease

Expression for Vestibulocochlear Nerve Disease

Search GEO for disease gene expression data for Vestibulocochlear Nerve Disease.

Pathways for Vestibulocochlear Nerve Disease

Pathways related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1
Show member pathways
10.89 ATP2B3 CACNA1A

GO Terms for Vestibulocochlear Nerve Disease

Biological processes related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 calcium ion transport GO:0006816 8.96 ATP2B3 CACNA1A
2 calcium ion transmembrane transport GO:0070588 8.62 ATP2B3 CACNA1A

Molecular functions related to Vestibulocochlear Nerve Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 metal ion binding GO:0046872 9.02 ATP2B3 CACNA1A PIR RTEL1 SALL1

Sources for Vestibulocochlear Nerve Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....